Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden.

Hirosumi SuzukiTakeshi YamadaAkinori SugayaShunsuke UeyamaYoshiyuki YamamotoToshikazu MoriwakiIchinosuke Hyodo

Published in: International journal of clinical oncology (2020)

Nivolumab could improve massive ascites and confer survival benefit for some AGC patients. Considering a similar incidence of immune-related adverse events, it would be a recommended treatment option for AGC with massive ascites.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
risk factors
radiation therapy
neoadjuvant chemotherapy
smoking cessation